Literature DB >> 8934050

Final results of the Royal College of Radiologists' trial comparing two different radiotherapy schedules in the treatment of cerebral metastases.

T J Priestman1, J Dunn, M Brada, R Rampling, P G Baker.   

Abstract

Between February 1990 and February 1993, 25 centres in the UK recruited 544 patients into a prospective randomized trial comparing two whole-brain radiotherapy regimens (30 Gy in ten fractions over 2 weeks versus 12 Gy in two fractions on consecutive days) for the treatment of patients with symptomatic cerebral metastases. Of these patients 533 were eligible for analysis: 270 assigned to the two-fraction arm and 263 to the ten-fraction arm. The two groups were well balanced with respect to patient characteristics. Median survival was 77 days with two fractions (95% CI 68-89) and 84 days for the longer schedule (95% CI 67-102). Analysis of the survival curves showed a marginal advantage for ten fractions (P = 0.04). Performance status (P = 0.0001), site of primary tumour (P = 0.006), dose of dexamethasone (P = 0.004), age (P = 0.04) and randomization treatment (P = 0.03) were independant factors associated with survival. The classification of patients into good or poor risk groups based on these factors, excluding treatment, showed highly significant differences in survival (P < 0.0001). Predictive models suggested that any benefit attributable to the longer radiotherapy schedule was confined to those in a good prognostic group (these patients formed 22% of the study population). Radiation related side effects, other than alopecia, were seen in 12% of patients receiving two fractions and 8% of those given ten fractions. The short survival of many patients hampered the assessment of response, but overall responses were seen in 39% of those given two fractions and 44% of patients receiving ten fractions. These results suggest that any increase in survival due to longer radiotherapy treatment is confined to good prognosis patients, but, for the majority, there is no advantage and the value of radiotherapy for these patients relates purely to the possibility of control or relief of distressing symptoms.

Entities:  

Mesh:

Year:  1996        PMID: 8934050     DOI: 10.1016/s0936-6555(05)80717-4

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  26 in total

Review 1.  Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future.

Authors:  Claudia Proto; Martina Imbimbo; Rosaria Gallucci; Angela Brissa; Diego Signorelli; Milena Vitali; Marianna Macerelli; Giulia Corrao; Monica Ganzinelli; Francesca Gabriella Greco; Marina Chiara Garassino; Giuseppe Lo Russo
Journal:  Transl Lung Cancer Res       Date:  2016-12

Review 2.  Clinical Management of Multiple Melanoma Brain Metastases: A Systematic Review.

Authors:  Sharad Goyal; Ann W Silk; Sibo Tian; Janice Mehnert; Shabbar Danish; Sinthu Ranjan; Howard L Kaufman
Journal:  JAMA Oncol       Date:  2015-08       Impact factor: 31.777

3.  Decision making in palliative radiation therapy: reframing hope in caregivers and patients with brain metastases.

Authors:  Jacqueline Sze; Stephen Marisette; Diane Williams; Joyce Nyhof-Young; Dauna Crooks; Amna Husain; Andrea Bezjak; Rebecca K S Wong
Journal:  Support Care Cancer       Date:  2006-02-25       Impact factor: 3.603

4.  Incidence of hospitalization in patients receiving short course palliative cranial radiotherapy on outpatient basis in a limited resource setting - Experience from a regional cancer center in India.

Authors:  Aparna Gangopadhyay; Joydeep Das; Partha Nath; Tapas Maji; Jaydip Biswas
Journal:  Rep Pract Oncol Radiother       Date:  2014-07-17

Review 5.  Breast cancer (metastatic).

Authors:  Justin Stebbing; Sarah Ngan
Journal:  BMJ Clin Evid       Date:  2010-09-08

6.  Incidence of symptomatic brain metastasis following radical radiotherapy for non-small cell lung cancer: is there a role for prophylactic cranial irradiation?

Authors:  E Khan; S Ismail; R Muirhead
Journal:  Br J Radiol       Date:  2012-09-19       Impact factor: 3.039

7.  The treatment of patients with 1-3 brain metastases: is there a place for whole brain radiotherapy alone, yet? A retrospective analysis.

Authors:  Michela Buglione; Sara Pedretti; Stefano Gipponi; Luciano Buttolo; Paolo Panciani; Pietro Luigi Poliani; Roberto Liserre; Paolo Borghetti; Ludovica Pegurri; Loredana Costa; Luca Triggiani; Nadia Pasinetti; Paolo Ghirardelli; Sara Pandini; Alessandro Padovani; Stefano Maria Magrini
Journal:  Radiol Med       Date:  2015-04-28       Impact factor: 3.469

Review 8.  The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline.

Authors:  Laurie E Gaspar; Minesh P Mehta; Roy A Patchell; Stuart H Burri; Paula D Robinson; Rachel E Morris; Mario Ammirati; David W Andrews; Anthony L Asher; Charles S Cobbs; Douglas Kondziolka; Mark E Linskey; Jay S Loeffler; Michael McDermott; Tom Mikkelsen; Jeffrey J Olson; Nina A Paleologos; Timothy C Ryken; Steven N Kalkanis
Journal:  J Neurooncol       Date:  2009-12-04       Impact factor: 4.130

Review 9.  Breast cancer (metastatic).

Authors:  Justin Stebbing; Sarah Slater; Maurice Slevin
Journal:  BMJ Clin Evid       Date:  2007-02-01

Review 10.  Prognostic indices for brain metastases--usefulness and challenges.

Authors:  Carsten Nieder; Minesh P Mehta
Journal:  Radiat Oncol       Date:  2009-03-04       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.